Author: jezzabellemente

KUALA LUMPUR, Sept 21 (Bernama) — Adagio Therapeutics Inc, a clinical-stage biopharmaceutical company has reported updates on its lead COVID-19 antibody programme, ADG20, as well as recent business highlights and second quarter 2021 financial results.

“Our team is working closely with our global CRO partners on the execution of our ongoing global clinical trials of ADG20, STAMP and EVADE, while also preparing for the anticipated worldwide commercialisation of ADG20, if approved,” said co-founder and chief executive officer of Adagio, Tillman Gerngross, Ph.D. in a statement.

ADG20 COVID-19 programme highlights include New ADG20 Data to be Presented in Multiple Posters during IDWeek; and, Partnership with Biocon Biologics Expands the Reach of a Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets.

At the IDWeek 2021 Virtual Conference, Adagio plans to present additional data highlighting the potential for ADG20 to provide protection from COVID-19 for up to one year based on its extended half-life in humans combined with its broad and potent neutralising ability demonstrated in laboratory testing.

Meanwhile, recent business highlights include David Hering, Global COVID-19 Vaccine Expert, Appointed as Chief Operating Officer; US$355.8 Million Initial Public Offering (IPO) Successfully Completed; and, Board of Directors Expanded with Industry Leaders to Support Future Growth.

In August 2021, Adagio sold 20,930,000 shares of common stock, including the full exercise of the underwriters’ option to purchase an additional 2,730,000 shares of common stock at a public offering price of US$17.00 per share. (US$1 = RM4.188)

In addition, as of June 30, Adagio had cash, cash equivalents and marketable securities of US$392.5 million, which includes net proceeds from its Series C financing completed in April, while pro forma cash, cash equivalents and marketable securities as of June 30 is US$719.6 million after giving effect to its initial public offering which closed on Aug 10.

Research & development expenses including in-process research and development for the second quarter of 2021 were US$37.6 million, while selling, general & administrative expenses for the second quarter of 2021 were US$7.1 million.

More details at http://www.adagiotx.com.

— BERNAMA

KUALA LUMPUR, Sept 21 (Bernama) — The Celltrion Group announced the Korean Ministry of Food and Drug Safety (MFDS) has approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19.

This is for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition (the obese, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents) with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19.

This marks the first time a monoclonal antibody treatment for COVID-19 has received full approval to treat patients with COVID-19 from the Korean MFDS, according to a statement.

“Recent clinical data have helped improve healthcare professionals’ and public health authorities’ understanding of the potential role of regdanvimab in the treatment of patients with mild-to-moderate symptoms of COVID-19,” said Head of Medical and Marketing Division at Celltrion Healthcare, Dr HoUng Kim, Ph.D.

The administration time for the recommended dosage of regdanvimab (CT-P59), a single intravenous (IV) infusion of 40 mg/kg, has been reduced from 90 minutes to 60 minutes.

Celltrion has successfully enrolled more than 1,315 people in its global Phase III clinical trial, which evaluated the efficacy and safety of regdanvimab (CT-P59) in 13 countries including the US, Spain, and Romania.

Data showed regdanvimab (CT-P59) significantly reduced the risk of COVID-19 related hospitalisation or death by 72 per cent for patients at high-risk of progressing to severe COVID-19 and 70 per cent for all patients.

In addition, pre- clinical data for regdanvimab (CT-P59) demonstrated strong neutralising activity against the Delta variant (B.1.617.2, first identified in India) with results showing 100 per cent survival rate with virus eradication from all animals treated with therapeutic dosage of CT-P59.

As of September 2021, more than 14,857 people have been treated with regdanvimab (CT-P59) in 107 hospitals in the Republic of Korea.

More details at https://www.celltrionhealthcare.com.

— BERNAMA

TOKYO, Sept. 17, 2021/Kyodo JBN-AsiaNet/–

– Meeting Set for October 2 to 5, 2021, Seeking Better Future of Humankind –

The STS forum is holding its 18th Annual Meeting from October 2 to 5, 2021. World leaders, including professional scientists, policymakers and business leaders, will gather online to discuss the pressing science and technology issues the world is facing and to build an international network.

Dates: Saturday, October 2, to Tuesday, October 5, 2021
Venue: LIVE ONLINE from Kyoto, Japan
Participation: By invitation only

Invitation requests can be submitted from https://www.stsforum.org/kyoto2021/.

Program
The forum will host 20 sessions online this year. Some examples of the topics are “Global Pandemic–Lessons Learned and Forecast,” “Green Recovery for Sustainable Society,” “Disruptive Technologies for Industries,” “The Second Quantum Revolution and Society,” “Lights and Shadows of Digital Economy,” and “Path Toward Net-Zero Emission.”

Confirmed speakers
More than 100 distinguished speakers, including 14 Novel laureates, have confirmed their online presence:

Policymakers:
– Mariya Gabriel, Commissioner, European Commission, EU
– Laksana Tri Handoko, Chairman, National Research and Innovation Agency, Indonesia
– Helen Elizabeth Clark, 37th Prime Minister of New Zealand

Business leaders:
– Nathan Myhrvold, Founder and Chief Executive Officer, Intellectual Ventures, U.S.A.
– Terry Brady, President and CEO, Underwriters Laboratories Inc., U.S.A.
– Ahmad O. Al-Khowaiter, Chief Technology Officer, Saudi Arabian Oil Company, Saudi Arabia

Academia:
– Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases, U.S.A.
– George Fu Gao, Director-General, Chinese Center for Disease Control and Prevention, China
– Gerald H. Haug, President, German National Academy of Sciences Leopoldina, Germany

International organization/media:
– Seth Berkley, CEO, Gavi, the Vaccine Alliance
– Magdalena Skipper, Editor-in-Chief, Nature, U.K.
– Holden Thorp, Editor-in-Chief, Science, U.S.A.

Entire program (updated daily):
https://www.stsforum.org/kyoto2021/

Online coverage available to the media
To register, please visit: https://www.stsforum.org/media/

Scenes from last year’s annual meeting:
https://kyodonewsprwire.jp/release/202109139960?p=images

YouTube:
https://www.youtube.com/watch?v=Z1ykQ8GL4Rc&ab_channel=STSforum
https://www.youtube.com/watch?v=pNtFlPkHuZk&ab_channel=STSforum

About STS forum
The STS forum, a non-profit organization founded in 2004, aims to provide a unique platform for the world’s top leaders to unite and discuss how to deal with science and technology issues from a long-term perspective for the future of humankind.
https://www.stsforum.org/


Source: STS forum (NPO) 

KUALA LUMPUR, Sept 17 (Bernama) — To celebrate the Mid-Autumn Festival and the joy of family reunions, VistaJet, the first and only global business aviation company, has introduced Moonlight Infusions.

For a limited time, clients are invited to celebrate the festival on board with a bespoke tea and mooncake pairing session, as well as a personalised Tea Flight Experience while basking in the beauty of the moon.

Executive Vice President of Marketing and Innovation at VistaJet, Matteo Atti said in a statement: “Mid- Autumn Festival is about spending quality time with family, be it in the air or on the ground.”

“Whether you are looking for a notable experience in the air or simply looking for the safest way to reunite with family, VistaJet is here to help anytime, anywhere, and create one of the most unforgettable memories for you at this special time of the year.”

Available from now throughout September 2021 for those departing from key Asian cities, Moonlight Infusions showcases highlights from VistaJet’s tea collection, including Red Dragon tea, Dragon Well, Iron Buddha and Vintage Imperial Puerh.

Clients will appreciate the teas with thoughtfully paired premium mooncakes. For example, Red Dragon is a unique black tea with an enticing fruity flavour and creamy note of chocolate, making a perfect combination when paired with a dense, rich red bean mooncake.

The bespoke Tea Flight Experience is also available upon request to VistaJet clients both on board and on the ground, guided virtually by tea masters who will take clients on an immersive journey through the world of tea and bring to life their signature varieties.

VistaJet also offers its clients the opportunity to embark on tea plantation journeys around the world, curated by Based on a True Story, enabling guests to connect with the origins, the people and culture behind the teas.

— BERNAMA

KUALA LUMPUR, Sept 15 (Bernama) — Procter & Gamble has announced a comprehensive plan to accelerate action related to climate change.

P&G has also set a new ambition to achieve net zero greenhouse gas (GHG) emissions across its operations and supply chain, from raw material to retailer, by 2040 as well as interim 2030 goals to make meaningful progress this decade.

“We are fully committed to use P&G’s innovation and ingenuity to unlock new solutions to address climate change,” said Chairman, P&G President and Chief Executive Officer, David S. Taylor in a statement.

“The task ahead of us is urgent, difficult and much bigger than any single company or country. P&G is tackling these challenges head-on by reducing our footprint and leveraging our scale to foster unprecedented collaboration across our value chain.”

The company’s 2030 goals to pace its progress toward net zero were submitted to The Science Based Targets initiative (SBTi): reducing emissions across operations by 50 per cent and reducing emissions across supply chain by 40 per cent.

It has joined the UN’s Race to Zero and the Business Ambition for 1.5°C campaigns and is also sharing its new Climate Transition Action Plan, which outlines a comprehensive approach to accelerating climate action and the key challenges ahead.

The company’s top priority is to significantly reduce GHG emissions as quickly as possible with solutions that exist today, including reducing emissions across operations; accelerating renewable electricity; and, decarbonising its supply chain and logistics.

The company knows there are some operational emissions cannot be eliminated yet and its teams are working hard to develop the next generation of low-carbon technologies and materials. Its efforts in this area include leveraging renewable thermal energy and advancing low-carbon technologies, materials, and packaging.

P&G is also going beyond its net zero ambition and doing more to make a collective impact – partnering with consumers to reduce GHG emissions from the use phase of products, creating alliances for carbon-efficient homes, and advocating for policy solutions to decarbonise energy infrastructure.

More details at http://www.pg.com.

— BERNAMA